Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) Income from Continuing Operations (2022 - 2025)

Historic Income from Continuing Operations for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to -$10.8 million.

  • Pharmaceuticals' Income from Continuing Operations fell 2802.46% to -$10.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$38.5 million, marking a year-over-year decrease of 4919.66%. This contributed to the annual value of -$38.1 million for FY2024, which is 4356.45% down from last year.
  • Pharmaceuticals' Income from Continuing Operations amounted to -$10.8 million in Q2 2025, which was down 2802.46% from -$10.1 million recorded in Q1 2025.
  • In the past 5 years, Pharmaceuticals' Income from Continuing Operations ranged from a high of -$3.3 million in Q4 2023 and a low of -$14.9 million during Q4 2022
  • Moreover, its 4-year median value for Income from Continuing Operations was -$7.8 million (2023), whereas its average is -$8.1 million.
  • Within the past 5 years, the most significant YoY rise in Pharmaceuticals' Income from Continuing Operations was 7782.11% (2023), while the steepest drop was 4747.3% (2023).
  • Over the past 4 years, Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$14.9 million in 2022, then surged by 77.82% to -$3.3 million in 2023, then tumbled by 156.48% to -$8.5 million in 2024, then fell by 28.02% to -$10.8 million in 2025.
  • Its Income from Continuing Operations stands at -$10.8 million for Q2 2025, versus -$10.1 million for Q1 2025 and -$8.5 million for Q2 2024.